Reportstack is one of the largest online libraries of market research publications. We are the fastest growing and most preferred provider of business intelligence in the market today. We partner with the world's top publishers and research houses to bring to you expert analysis, accurate data and market information along with the best customer support and user experience. For more details, please visit www.reportstack.com
Monday, 22 May 2017
Detailed Study of the Global Rheumatoid Arthritis Drug Market 2025
PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 is a new market research publication announced by Reportstack. Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025.
The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2015 and 2025. With the anti-TNFs as extremely effective for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars launch across the 8MM and begin to gain traction in these markets.
- Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations. - Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets. - Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte’s Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune’s mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita). - Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the RA market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the eight major RA markets from 2015-2025. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
AbbVie Pfizer Amgen Johnson & Johnson Eli Lilly Bristol-Myers Squibb UCB Roche GlaxoSmithKline Sanofi AstraZeneca- MedImmune Astellas Daiichi Sankyo Samsung Bioepis Sandoz